Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.01562-2018
Abstract: Background Anlotinib has been demonstrated in clinical trials to be effective in prolonging the progression-free survival (PFS) and overall survival (OS) of refractory advanced nonsmall cell lung cancer (NSCLC) patients. However, the underlying molecular mechanisms… read more here.
Keywords: anti angiogenesis; nsclc patients; anlotinib; nonsmall cell ... See more keywords
Anlotinib-Induced Hypertension: Current Concepts and Future Prospects.
Sign Up to like & getrecommendations! Published in 2021 at "Current pharmaceutical design"
DOI: 10.2174/1381612827666211006145141
Abstract: BACKGROUND Anlotinib is a new tyrosine kinase inhibitor developed in China that targets the receptors for vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, and stem cell factor. Therefore, anlotinib inhibits tumor angiogenesis,… read more here.
Keywords: growth factor; induced hypertension; anlotinib induced; hypertension ... See more keywords